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Abstract— Tight glycemic control (TGC) is prevalent in 
critical care. Providing safe, effective TGC has proven very 
difficult to achieve with clinically derived protocols. The prob-
lem is exacerbated by extreme patient variability and the need 
to minimize clinical effort and burden. These ingredients make 
an ideal scenario for model-based methods to provide opti-
mised solutions. This paper presents the development, clinical-
ly validated virtual trials optimisation, and initial clinical 
implementation of a stochastic targeted (STAR) TGC method 
and framework. It is compared to a prior successful, model-
derived, less flexible and dynamic TGC protocol (SPRINT). 
The use of stochastic models to safely forecast a range of glu-
cose outcomes over 1-3 hours ensures better performance, 
more dynamic use of the range of insulin and nutrition inputs 
and thus better glycemic performance and safety from hypo-
glycemia, the latter of which was reduced by 3.0x times. Hence, 
the paper presents an overall engineering approach to TGC 
from engineering models to clinical implementation and ongo-
ing clinical practice change. 
Keywords— ICU, TGC, glycemic control, control systems, 
modelling, hypoglycemia, clinical trials. 
I. INTRODUCTION  
Hyperglycaemia is prevalent in critical care, associated 
with increased cost, morbidity and mortality [1], due to 
several factors relating to the stress of patient condition [2]. 
Effective tight glycaemic control (TGC) can significantly 
reduce negative outcomes by modulating nutrition and/or 
insulin administration [3, 4]. However, consistent, effective 
TGC remains elusive [5].  
A range of prior work successfully developed and vali-
dated metabolic system models [6, 7] and implemented a 
‘model-derived’ protocol, SPRINT [3]. SPRINT is currently 
employed in the Christchurch ICU and effectively reduced 
mortality by 20-45% and per patient costs by $1000-2000 
per-patient [3]. It has also been shown to reduce the rate and 
severity of organ failure by 10% [8]. Unlike all other pub-
lished protocols with similar glycaemic targets [5], it also 
reduced the incidence of hypoglycaemia by 50%. 
However, SPRINT has a fixed glycaemic target and lacks 
flexibility in several areas. It also offers no forecasting ca-
pabilities, is not easily customised to individual patients, 
and thus lacks the capacity to account for the wide range of 
metabolic variability observed in ICU patients [9, 10] 
This paper presents a novel, model-based, software con-
trol algorithm for the implementation of patient-specific 
TGC. It achieves accuracy of control similar to, or exceed-
ing, that delivered by SPRINT, while reducing measure-
ments and clinical effort. Uniquely, it can guarantee a re-
duced, clinically specified risk of hypoglycaemia. These 
outcomes are delivered within a flexible framework offering 
a range of clinical approaches and targets  
II. METHODS 
A. Patients 
Virtual trials are a safe means of optimising glycaemic 
control robustness, performance, safety from hypoglycae-
mia, and clinical burden [7, 11]. Done in silico, it is also 
much faster and lower cost than a strictly clinical protocol 
design approach. The TGC algorithm presented is tested 
using clinically validated [7] virtual patient simulations. The 
entire 371 patient SPRINT Cohort was used to create virtual 
patients for protocol design and analysis. 
 
B. Model 
The metabolic system model used is defined [7]: 
  (1) 
    (2) 
  (3) 
   (4) 
  (5) 
    (6) 
 
Model parameters and values are described in Table 1. Insu-
lin sensitivity SI is identified hourly enabling virtual patients 
and trials [6, 7]. 
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Table 1: Model parameters and values 
 Description Values 
G Blood glucose level (mmol/L) 
pG 
Insulin independent glucose removal 
(excluding central nervous system 
uptake) and the suppression of EGP 
from EGPb with respect to G 
0.006 (min−1) 
αG 
Saturation parameter for insulin medi-
ated glucose removal 1/65 (L/mU) 
SI 
Insulin mediated glucose removal and 
the suppression of EGP from EGPb 
with respect to G and Q 
(L/mU/min) 
Q Interstitial insulin concentration (mU/L) 
P(t) Glucose appearance in plasma from dextrose intake (mmol/min) 
EGP Endogenous glucose production 1.16 (mmol/min) 
CNS Central nervous system glucose uptake 0.3 (mmol/min) 
VG Plasma glucose distribution volume 13.3 (L) 
k Interstitial insulin transport rate - ln(0.5)/35 (min−1) 
I Plasma insulin concentration (mU/L) 




Saturation parameter for plasma  
insulin clearance  
1.7 x 10-3 
(L/mU) 
uex(t) Exogenous insulin (mU/min) 
VI Plasma insulin distribution volume 3.15 (L) 
d2 Glucose absorption rate from gut 
-ln(0.5)/100 
(min−1) 
P2 Glucose level in gut (mmol) 
Pmax 




P1 Glucose level in stomach (mmol) 
d1 Glucose absorption rate from stomach 
-ln(0.5)/20 
(min−1) 
D(t) Dextrose intake (mmol/min) 
 
Time-variable insulin sensitivity profiles (SI(t)), created 
from patient data, are identified hourly from clinical data 
[6]. SI has been extensively validated for in silico virtual 
patients and accurate predictions [7]. 
 
C. Stochastic Model and Target-to-Range 
The Stochastic Targeted (STAR) TGC protocol presented 
optimises treatment based on a stochastic model [9, 10] of 
the potential variability in SI(t) over the following 1-3 
hours. This variability results in a range of likely BG out-
comes for any given insulin and nutrition intervention, in-
cluding the median, IQR and 90% confidence interval.  
STAR modulates both insulin and nutrition, or just insu-
lin for a fixed nutritional input. The controller examines all 
possible combinations for each of 1, 2 and 3 hour forward 
intervals, within certain constraints. Specifically: 
 
• Insulin rates can increase by no more than 3U/hour 
• Feed rate changes are limited to 20% of goal feed 
 
Within these limits all possible insulin and nutrition inter-
ventions are considered to reach target.  
 The controller targets a clinically specified range. In 
this case, the range of 4.0-6.5 mol/L. For 1-hour interven-
tions the 95th percentile outcome is set on 6.5 mmol/L. For 2 
and 3 hour interventions, the 5th percentile outcome is tar-
geted to 4.5mmol/L and recognises the potential loss of 
some control to a safer (than hypoglycemia) level above 6.5 
mmol/L in some cases. 
 In all cases, the 5th percentile is never set lower than 4.0 
mmol/L guaranteeing a maximum risk of 5% of very mod-
erate hypoglycemia less than this value. 
 
D. Analyses and Clinical Proof of Concept 
The following virtual trials were run to assess STAR: 
 
• Measurement interval limited to 1 hour – Best Case 
• Measurement interval limited to 2 hours (when 
available) – Intermediate Case 
• Measurement interval not limited (up to 3 hours) 
and longest available selected – Minimum Clinical 
Effort Case 
 
The 2 hour limited intervals case is the closest comparator 
to the clinical SPRINT data. 
 Clinical pilot trials were run for 7 patients. Their data is 
presented similarly for broad comparison. Each patient was 
individually consented, with approval granted by the NZ 
South Island Regional Ethics Committee. 
III. RESULTS AND DISCUSSION 
A. Virtual Trial Results 
Tables 2-3 show the performance and safety from hypo-
glycemia results for the in silico virtual trials. It is clear that 
performance is comparable or improved from SPRINT, as 
desired. More importantly, safety from hypoglycemia is 
significantly reduced at all measurement intervals compared 
to SPRINT, particularly in numbers of patients exposed to 
severe hypoglycemia (BG < 2.2 mmol/L), which is as ex-
pected given the stochastic targeting methods used. 
 
Table 2: Performance results in silico 1, 2, 3 hour intervals 
 1 hour 2 hour 3 hour SPRINT 
BG median [IQR] 
(mmol/L) 
5.8 
[5.3 - 6.4] 
5.8 
[5.2 - 6.8] 
6.1 
[5.3 - 7.1] 
5.7 
[5.0 – 6.6] 
% BG: 4.0 - 6.5 75 66 58 70 
% BG: 5.0 - 6.5  64 50 45 50 
% BG: 4.0 – 8.0  93 87 84 88 
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Table 3: Safety from hypoglycemia performance (No. of 371 total) 
 1-hour 2-hour 3-hour SPRINT 
No. < 2.2mmol/L 6 6 8 13 
% BG < 4.0mmol/L 1.1 3.0 3.5 3.8 
No. < 4.0mmol/L 129 187 179 283 
 
For clarity the patient-specific cumulative distribution 
functions (CDFs) are shown for SPRINT and STAR 2 hour 
measurement intervals in Figures 1-4. These figures show 
the CDF for each patient as grouped around the median 
patient. The 5th and 95th percentile patients represent the 
outliers of over and under control of BG, while the 25th and 
75th percentiles show the band within which the central 
tendency and overall expected outcome lies. The 2-hour 
measurement interval analysis of STAR, in which the long-
est allowed measurement interval is 2-hours comparable to 
SPPRINT, shows, as in Table 2, very similar results. As 
expected, using 3-hour intervals results in a slight loss of 
control and using only 1-hour intervals provides very tight 
control. The tradeoff is in clinical effort, where 2-3 hour 






























































Figure 4: SPRINT clinical, patient specific BG CDFs 
 
In particular, the reduced risk of hypoglycaemia across 
patients can also be seen. Figures 1-4 compare the median 
patient across each case. The 5th percentile patients show 
safety. It is clear that the median SPRINT patient had some 
BG < 4.0mmol/L, where the median STAR patient did not, 
indicating greater safety with this approach for greater 
numbers of patients, as well as comparable or better overall 
performance. 
 
B. Clinical Proof of Concept Trials 
At the time of this writing, 7 patients had been consented 
and been treated with STAR for the entire length of ICU 
stay requiring glycemic control. Tables 4-5 summarise the 
results from these trials in the same format as Tables 2-3 for 
comparison. For comparison, the results from virtual trials 
on these 7 patients, using SPRINT with the nutrition given 
in these clinical trials, and as would have been given if 
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Table 4: Performance results STAR trials versus SPRINT in silico 






[5.2 - 68] 
5.7 
[4.7 - 6.8] 
5.3 
[4.6 – 6.0] 
% BG: 4.0 - 6.5 63 57 72 
% BG: 5.0 - 6.5  76 68 79 
% BG: 4.0 – 8.0  90 84 87 
 
Table 5: Safety of STAR versus SPRINT in silico 
 STAR SPRINT w/ feed from 
STAR 
SPRINT 
No. < 2.2mmol/L 0 2 3 
% BG < 4.0mmol/L 4.5 10.4 12.5 
 
With respect to performance it is clear that STAR has 
comparably tight control, and exceeds SPRINT in the 4.0-
8.0 mmol/L band. The difference is seen primarily in safety 
where there is no severe hypoglycemia in STAR, which had 
a minimum measurement of 3.8 mmol/L over all 404 BG 
measurements. Equally, the percentage of measurements 
below 4.0 mmol/L is less than 5%, as guaranteed by STAR, 
and 2.5-3.0 times less than for SPRINT. 
These seven patients comprised a total of 660 hours of 
control. There were 404 measurements, for an average of 
14.5 measurements per day. This value is a reduction from 
the 17 per day in SPRINT and indicates a clinical time sav-
ings of approximately 12-15 minutes per day, which is rela-
tively significant when added up across shifts. It is also near 
the in silico prediction of 14 per day when using STAR 2-
hour. Importantly, nursing staff tended not to choose 3-
hourly measurements in these trials, for a range of reasons 
from safety to habit from SPRINT. 
The SPRINT analyses in Tables 4-5 are somewhat differ-
ent. The first uses the same nutrition rates as STAR used in 
its trials, so it thus compares the insulin administration 
choices only. It is far more variable and distinctly underper-
forms. The second analysis, uses SPRINT is comparable to 
its overall reported clinical performance and to STAR, ex-
cepting the relatively high rate of moderate hypoglycemia. 
Hence, STAR was less variable, as seen in Figures 1-4 as 
well with the steeper and more tightly grouped CDFs. 
Regarding the two SPPRINT comparison virtual trials, 
the insulin and feed administration was very different. In 
particular, SPRINT tends to use lower nutritional dextrose 
administration rates, which was seen in these virtual trials 
where the cohort median [IQR] dextrose administration was 
4.5 [4.4, 4.9] g/hour for SPRINT and a much higher and 
more variable 6.8 [5.8, 8.7] g/hour for STAR. These inputs 
were offset by insulin rates of 3.0 [2.0, 3.0] U/hour for 
SPRINT and, an again much more variable, 2.5 [0.0, 6.0] 
U//hour for STAR.  
Hence, it is clear that the STAR controller achieves its 
better results by a more dynamic use of the full range of 
control inputs (dextrose and insulin administration). This 
ability is provided by the stochastic forecasting methods 
unique to this approach that enable more significant inputs, 
when warranted and provably safe via stochastic forecast-
ing. As a result, the clinician receives comparable perfor-
mance and better safety. 
IV. CONCLUSIONS  
This research presented an overall stochastic targeted 
(STAR) approach to TGC in critical care. It shows how to 
take a method from a model and data, to analysis and into 
clinical practice using clinically validated in silico virtual 
trials to safely optimise a protocol without clinical risk.  
The overall STAR approach is unique in its stochastic 
forecasting ability. As a result, it can utilise more dynamic 
ranges of control inputs, more safely, and with less clinical 
intervention or burden. These are unique, compromise bust-
ing outcomes for the field. Hence, these results also validate 
the overall model-based approach presented that can rapidly 
take a clinical intervention from engineering and ideas to 
clinical practice change. 
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